# US 2025/0144230 A1 · Linkers for use in antibody drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144230 A1
- Document ID: US20250144230A1
- Status: Published application
- Kind: A1
- Application number: 18/690,506
- Filed: 2022-09-07
- Published: 2025-05-08
- Earliest claimed: 2021-09-08
- Assignees: Orum Therapeutics Inc.
- Applicants: Orum Therapeutics, Inc.
- Inventors: Nathan FISHKIN; Chen BAI; Khuloud TAKROURI; Peter U. PARK
- Web page: https://patentgrep.com/patent/US20250144230A1

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6867: {the tumour determinant being from a cell of a blood cancer}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides traceless linkers, which can link an inducer of protein-protein interaction to a cell binding agent. Also provided are compositions comprising the linked compounds. The compounds and compositions are useful for treating diseases such as cancer in subjects in need thereof.

## Claims

### Claim 1

A conjugate of formula (XXXII):
or a pharmaceutically acceptable salt thereof, wherein:
a is from 1 to 10;
A′ is
wherein
n is 0 or 1;
each Y is independently S or 0;
indicates the point of attachment to R1; and
indicates the point of attachment to the methylene group;
R1, together with A′, is a compound that induces a protein-protein interaction;
R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-A′, and a group that provides stability and solubility to R1-A′;
L is a cleavable linker; and
Bm is a binding moiety that is capable of specifically binding to a protein.

### Claim 2

A conjugate of formula (XX):
or a pharmaceutically acceptable salt thereof, wherein:
a is from 1 to 10;
n is 0 or 1;
R1 is a compound that induces a protein-protein interaction;
R2 is selected from hydrogen, —(CH2CH2O)v—CH3, C2-C6alkenyl, C1-C6alkyl; C2-C6alkynyl, benzyl, C3-C6cycloalkyl, and C3-C6cycloalkyl(C1-C3alkyl), wherein v is from 1 to 24;
each Y is independently S or 0;
L is a cleavable linker; and
Bm is a binding moiety that is capable of specifically binding to a protein.

### Claim 3 (depends on 1, 2)

The conjugate of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the binding moiety is an antibody, antibody fragment, or an antigen-binding fragment.

### Claim 4 (depends on 1, 2, 3)

The conjugate of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein a is from 2 to 8.

### Claim 5 (depends on 1, 2, 3, 4)

The conjugate of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the linker is cleavable by a protease.

### Claim 6 (depends on 5)

The conjugate of claim 5, or a pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of
wherein:
q is from 2 to 10;
Z1, Z2, Z3, Z4, and Z5 are each independently absent or a naturally-occurring amino acid residue in the L- or D-configuration, provided that at least two of Z1, Z2, Z3, Z4, and Z5 are amino acid residues;
is the point of attachment to the parent molecular moiety; and
is the point of attachment to the binding moiety.

### Claim 7 (depends on 6)

The conjugate of claim 6, or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, Z4, and Z5 are independently absent or selected from the group consisting of L-valine, D-valine, L-citrulline, D-citrulline, L-alanine, D-alanine, L-glutamine, D-glutamine, L-glutamic acid, D-glutamic acid, L-aspartic acid, D-aspartic acid, L-asparagine, D-asparagine, L-phenylalanine, D-phenylalanine, L-lysine, D-lysine, and glycine; provided that at least two of Z1, Z2, Z3, Z4, and Z5 are amino acid residues.

### Claim 8 (depends on 7)

The conjugate of claim 7, or a pharmaceutically acceptable salt thereof, wherein:
Z1 is absent or glycine;
Z2 is absent or selected from the group consisting of L-glutamine, D-glutamine, L-glutamic acid, D-glutamic acid, L-aspartic acid, D-aspartic acid, L-alanine, D-alanine, and glycine;
Z3 is selected from the group consisting of L-valine, D-valine, L-alanine, D-alanine, L-phenylalanine, D-phenylalanine, and glycine;
Z4 is selected from the group consisting of L-citrulline, D-citrulline, L-asparagine, D-asparagine, L-lysine, D-lysine, L-phenylalamine, D-phenylalanine, and glycine; and
Z5 is absent or glycine.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The conjugate of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L is

### Claim 10 (depends on 9)

The conjugate of claim 9, or a pharmaceutically acceptable salt thereof, wherein q is 4.

### Claim 11 (depends on 1, 2, 3, 4)

The conjugate of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein L is a bioreducible linker.

### Claim 12 (depends on 11)

The conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of
wherein:
q is from 2 to 10;
R, R′, R″, and R′″ are each independently selected from hydrogen, C1-C6alkoxyC1-C6alkyl, (C1-C6)2NC1-C6alkyl, and C1-C6alkyl, or, two geminal R groups, together with the carbon atom to which they are attached, can form a cyclobutyl or cyclopropyl ring;
is the point of attachment to the parent molecular moiety; and
is the point of attachment to the binding moiety.

### Claim 13 (depends on 12)

The conjugate of claim 12, or a pharmaceutically acceptable salt thereof, wherein L is

### Claim 14 (depends on 13)

The conjugate of claim 13, or a pharmaceutically acceptable salt thereof, wherein q is 2.

### Claim 15 (depends on 1, 2, 3, 4)

The conjugate of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein L is a click-to-release linker.

### Claim 16 (depends on 15)

The conjugate of claim 15, or a pharmaceutically acceptable salt thereof, wherein L is
wherein:
q is from 2 to 10;
is the point of attachment to the parent molecular moiety; and
is the point of attachment to the binding moiety.

### Claim 17 (depends on 1, 2, 3, 4)

The conjugate of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein L is a beta-glucuronidase cleavable linker.

### Claim 18 (depends on 15)

The conjugate of claim 15, or a pharmaceutically acceptable salt thereof, wherein L is
wherein:
q is from 2 to 10;
- - - is absent or a bond;
is the point of attachment to the parent molecular moiety; and
is the point of attachment to the binding moiety.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The conjugate of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein L is attached to a cysteine, lysine, tyrosine, or glutamine in the Bm.

### Claim 20 (depends on 19)

The conjugate of claim 19, or a pharmaceutically acceptable salt thereof, wherein the cysteine or lysine is an engineered cysteine or lysine.

### Claim 21 (depends on 19)

The conjugate of claim 19, or a pharmaceutically acceptable salt thereof, wherein the cysteine or lysine is endogenous to the Bm.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The conjugate of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein Bm is an antibody or antigen binding portion thereof.

### Claim 23 (depends on 22)

The conjugate of claim 22, wherein L is attached to an engineered cysteine at heavy chain position S239 and/or K334 of the antibody or antigen binding portion thereof according to EU numbering.

### Claim 24 (depends on 22)

The conjugate of claim 22, wherein L is attached to the glutamine at heavy chain position 295 of the antibody or antigen binding portion thereof according to EU numbering.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The conjugate of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein the protein that the Bm binds to is a surface antigen, optionally wherein binding of the Bm to the surface antigen results in internalization of the conjugate or pharmaceutically acceptable salt thereof into a cell.

### Claim 26 (depends on 25)

The conjugate of claim 25, or a pharmaceutically acceptable salt thereof, wherein the surface antigen comprises 5T4, ACE, ADRB3, AKAP-4, ALK, AOC3, APP, Axin1, AXL, B7H3, B7-H4, BCL2, BCMA, bcr-ab1, BORIS, BST2, C242, C4.4a, CA 125, CA6, CA9, CAIX, CCL11, CCR5, CD123, CD133, CD138, CD142, CD15, CD15-3, CD171, CD179a, CD18, CD19, CD19-9, CD2, CD20, CD22, CD23, CD24, CD25, CD27L, CD28, CD3, CD30, CD31, CD300LF, CD33, CD352, CD37, CD38, CD4, CD40, CD41, CD44, CD44v6, CD5, CD51, CD52, CD54, CD56, CD62E, CD62P, CD62L, CD70, CD71, CD72, CD74, CD79a, CD79b, CD80, CD90, CD97, CD125, CD138, CD141, CD147, CD152, CD154, CD326, CEA, CEACAM5, CFTR, clumping factor, cKit, Claudin 3, Claudin 18.2, CLDN6, CLEC12A, CLL-1, cll3, c-MET, Crypto 1 growth factor, CS1, CTLA-4, CXCR2, CXORF61, Cyclin B1, CYP1B1, Cadherin-3, Cadherin-6, DLL3, E7, EDNRB, EFNA4, EGFR, EGFRvIII, ELF2M, EMR2, ENPP3, EPCAM, EphA2, Ephrin A4, Ephrin B2, EPHB4, ERBB2 (Her2/neu), ErbB3, ERG (TMPRSS2 ETS fusion gene), ETBR, ETV6-AML, FAP, FCAR, FCRL5, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, Folate receptor alpha, Folate receptor beta, FOLR1, Fos-related antigen 1, Fucosyl GM1, GCC, GD2, GD3, GloboH, GM3, GPC1, GPC2, GPC3, gplOO, GPNMB, GPR20, GPRC5D, GUCY2C, HAVCR1, HER2, HER3, HGF, HMI.24, HMWMAA, HPV E6, hTERT, human telomerase reverse transcriptase, ICAM, ICOS-L, IFN-α, IFN-γ, IGF-I receptor, IGLL1, IL-2 receptor, IL-4 receptor, IL-13Ra2, IL-1 1Ra, IL-1 receptor, IL-12 receptor, IL-23 receptor, IL-13 receptor, IL-22 receptor, IL-4 receptor, IL-5 receptor, IL-6 receptor, interferon receptor, integrins (including α4, αvβ3, αvβ5, αvβ6, α1β4, α4β1, α4β7, α5β1, α6β4, αIIbβ3 intergins), Integrin alphaV, intestinal carboxyl esterase, KIT, LAGE-1a, LAIR1, LAMP-1, LCK, Legumain, LewisY, LFA-I (CDI 1a), L-selectin (CD62L), LILRA2, LIV-1, LMP2, LRRC15, LY6E, LY6K, LY75, MAD-CT-1, MAD-CT-2, MAGE A1, MelanA/MARTl, Mesothelin, ML-IAP, MSLN, mucin, MUC1, MUC16, mut hsp70-2, MYCN, myostatin, NA17, NaPi2b, NCA-90, NCAM, Nectin-4, NGF, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NY-BR-1, NY-ESO-1, o-acetyl-GD2, OR51E2, OY-TES1, p53, p53 mutant, PANX3, PAP, PAX3, PAX5, p-CAD, PCTA-1/Galectin 8, PD-L1, PD-L2, PDGFR, PDGFR-beta, phosphatidylserine, PIK3CA, PLAC1, Polysialic acid, Prostase, prostatic carcinoma cell, prostein, Pseudomonas aeruginosa, rabies, survivin and telomerase, PD-1, PRSS21, PSCA, PSMA, PTK7, RAGE-1, RANKL, Ras mutant, respiratory syncytial virus, Rhesus factor, RhoC, RON, ROR1, ROR2, RU1, RU2, sarcoma translocation breakpoints, SART3, SLAMF7, SLC44A4, sLe, SLITRK6, sperm protein 17, sphingosine-1-phosphate, SSEA-4, SSX2, STEAP1, TAG72, TARP, TCRP, TEM1/CD248, TEM7R, tenascin C, TF, TGF-1, TGF-β2, TNF-α, TGS5, Tie 2, TIM-1, Tn Ag, TRAC, TRAIL-R1, TRAIL-R2, TROP-2, TRP-2, TRPV1, TSHR, tumor antigen CTAA16.88, tyrosinase, UPK2, VEGF, VEGFR1, VEGFR2, vimentin, WT1, XAGE1, or combinations thereof, optionally wherein the Bm that binds to CD33 comprises the amino acid sequences of SEQ ID NOs:1 and 2, 3 and 4, 5 and 6, 22, and 23, 24 and 25, or 27 and 28, wherein the Bm that binds to PSMA comprises the amino acid sequences of SEQ ID NOs:7 and 8, 9 and 10, 11 and 12, or 29 and 30, wherein the Bm that binds to HER2 comprises the amino acid sequences of SEQ ID NOs:13 and 14, 15 and 16, or 17, and 18, wherein the Bm that binds to CD20 comprises the amino acid sequences of SEQ ID NOs:31 and 32, wherein the Bm that binds to CD79b comprises the amino acid sequences of SEQ ID NO:33 and 34, or wherein the Bm that binds to BCMA comprises the amino acid sequences of SEQ ID NOs:35 and 36.

### Claim 27 (depends on 25)

The conjugate of claim 25, or a pharmaceutically acceptable salt thereof, wherein the surface antigen comprises HER2, CD20, CD38, CD33, BCMA, CD138, EGFR, FGFR4, GD2, PDGFR, or combinations thereof.

### Claim 28 (depends on 22)

The conjugate of claim 22, or a pharmaceutically acceptable salt thereof, wherein the antibody is selected from the group consisting of rituximab, trastuzumab, gemtuzumab, pertuzumab, obinutuzumab, ofatumumab, daratumumab, STI-6129, lintuzumab, huMy9-6, belantamab, indatuximab, cetuximab, dinutuximab, anti-CD38 A2 antibody, huAT15/3 antibody, alemtuzumab, ibritumomab, tositumomab, bevacizumab, panitumumab, tremelimumab, ticilimumab, catumaxomab, oregovomab, veltuzumab, polatuzumab, J591, lorvotuzumab and sacituzumab.

### Claim 29 (depends on 28)

The conjugate of claim 28, or a pharmaceutically acceptable salt thereof, wherein the antibody is rituximab, trastuzumab, pertuzumab, huMy9-6, lintuzumab, gemtuzumab, or CD33-D.

### Claim 30 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The conjugate of any one of claim 1 or 3 to 29, or a pharmaceutically acceptable salt thereof, wherein R2 is a group that provides stability to the conjugate.

### Claim 31 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The conjugate of any one of claim 1 or 3 to 30, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from C2-C6alkenyl, C1-C6alkyl; C2-C6alkynyl, benzyl, C3-C6cycloalkyl, and C3-C6cycloalkyl(C1-C3alkyl).

### Claim 32 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The conjugate of any one of claim 1 or 3 to 31, or a pharmaceutically acceptable salt thereof, wherein R2 is C1-C6alkyl.

### Claim 33 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The conjugate of any one of claim 1 or 3 to 32, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl.

### Claim 34 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The conjugate of any one of claim 1 or 3 to 29, or a pharmaceutically acceptable salt thereof, wherein R2 is a group that provides solubility to the conjugate.

### Claim 35 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The conjugate of any one of claims 1, 3 to 29, or 34, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from:
wherein:
each n is independently 1, 2, 3, 4, or 5;
each y is independently 1 or 2; and
each R is independently hydrogen, C6H11O5, C12H21O10, C18H31O15, or C24H41O20.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The conjugate of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein each Y is O.

### Claim 37 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The conjugate of any one of claim 1 or 3 to 36, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a PPI modulator.

### Claim 38 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The conjugate of any one of claim 1 or 3 to 36, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a targeted protein degrader.

### Claim 39 (depends on 1)

The conjugate of any one of claim 1, or 3 to 38, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a molecular glue.

### Claim 40 (depends on 1)

The conjugate of any one of claim 1, or 3 to 39, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a substituted isoindoline.

### Claim 41 (depends on 1)

The conjugate of any one of claim 1, or 3 to 40, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a 5′-substituted isoindoline.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The conjugate of any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, wherein R1 is a compound of formula (XXX):
wherein:
denotes the point of attachment to the parent molecular moiety;
A is phenyl or a C4-C10cycloalkyl ring;
R10 is independently selected from hydrogen and halo;
U is selected from NH and CF2; and
R20 is selected from —CH3, —C(O)R3, —N(R4)2, —(CH2)nOH, —(CH2)nN(R4)2, —(CH2)nQ′(CH2)mOH, —(CH2)nQ′(CH2)mSH, and —(CH2)nQ′(CH2)mN(R4)2; wherein
R3 is hydrogen or C1-C6alkyl;
each R4 is independently hydrogen or C1-C6alkyl;
Q′ is O, S, or NR4;
n is 1-6; and
m is 2-5.

### Claim 43 (depends on 42)

The conjugate of claim 42, or a pharmaceutically acceptable salt thereof, wherein
A is phenyl;
U is NH;
R10 is halo; and
R20 is methyl.

### Claim 44 (depends on 42)

The conjugate of claim 42, or a pharmaceutically acceptable salt thereof, wherein
A is phenyl;
U is NH;
R10 is halo; and
R20 is —(CH2)2O(CH2)2NHCH3.

### Claim 45 (depends on 1)

The conjugate of any one of claim 1, or 3 to 38, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a proteolysis targeting chimera (PROTAC).

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 45)

The conjugate of any one of claims 1 to 38 or 45, or a pharmaceutically acceptable salt thereof, wherein R1 has the formula:
POI-L100-CBN;
wherein:
POI is a compound that binds to a protein of interest;
L100 is a PROTAC linker; and
CBN is a cereblon binding moiety.

### Claim 47 (depends on 46)

The conjugate of claim 46, or a pharmaceutically acceptable salt thereof, wherein the protein of interest is a nuclear hormone receptor, a translation termination factor, a transcription factor, a cyclin-dependent kinase, a tyrosine kinase, a serine/threonine kinase, or an E3 ligase.

### Claim 48 (depends on 46, 47)

The conjugate of claim 46 or 47, or a pharmaceutically acceptable salt thereof, wherein the protein of interest is selected from CD33, GSPT1, BRD4, AR, ER, IKZF1/3, CK1a, BCL-XL, IKZF2, IRAK4, BTK, STAT3, BTK and iMiD, BRD9, TRK, MDM2, CDK2/CDK9, CD97b, and EGFR.

### Claim 49 (depends on 46, 47, 48)

The conjugate of any one of claims 46 to 48, or a pharmaceutically acceptable salt thereof, wherein L100 comprises one or more functional groups selected from glycol, alkyl, alkynyl, triazolyl, piperazinyl, piperidinyl, and combinations thereof.

### Claim 50 (depends on 46, 47, 48, 49)

The conjugate of any one of claims 46 to 49, or a pharmaceutically acceptable salt thereof, wherein CBN is selected from
wherein
indicates the point of attachment to A′; and
indicates the point of attachment to L100.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38)

The conjugate of any one of claims 1 to 36, 38, or 45 to 50, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from
wherein denotes the point of attachment to A′.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The conjugate of any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, wherein (a) the protein that the Bm binds to is CD33 and R1 binds to mouse double minute 2 homolog (MDM2), (b) the protein that the Bm binds to is prostate specific membrane antigen (PSMA) and R1 binds to androgen receptor (AR), (c) the protein that the Bm binds to is CD33 and R1 binds to bromodomain-containing protein 4 (BRD4), (d) the protein that the Bm binds to is HER2 and R1 binds to G1 to S Phase Transition 1 (GSPT1), (e) the protein that the Bm binds to is CD33 and R1 binds to GSPT1, (f) the protein that the Bm binds to is CD79b and R1 binds to IRAK4, (g) the protein that the Bm binds to is HER2 and R1 binds to BRD4, (h) the protein that the Bm binds to is BCMA and R1 binds to BRD4, or (i) the protein that the Bm binds to is HER2 and R1 binds to ER.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A pharmaceutical composition comprising a conjugate of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutically acceptable amount of a conjugate or composition of any of claims 1 to 53, or a pharmaceutically acceptable salt thereof.

### Claim 55 (depends on 54)

The method of claim 54, wherein the cancer is breast cancer, gastric cancer, lymphoma, acute myeloid leukemia, multiple myeloma, head and neck cancer, squamous cell carcinoma, hepatocellular carcinoma, prostate cancer, non-small cell lung cancer, colon cancer, ovarian cancer, neuregulin-1 (NRG1)-positive cancer, lung cancer, or non-Hodgkin lymphoma.

### Claim 56 (depends on 54)

The method of claim 54, wherein (a) the protein that the Bm binds to is CD33, R1 binds to MDM2, and the cancer is acute myeloid leukemia, (b) the protein that the Bm binds to is prostate specific membrane antigen (PSMA), R1 binds to androgen receptor (AR), and the cancer is prostate cancer, (c) the protein that the Bm binds to is CD33, R1 binds to bromodomain-containing protein 4 (BRD4), and the cancer is acute myeloid leukemia, (d) the protein that the Bm binds to is HER2, R1 binds to G1 to S Phase Transition 1 (GSPT1), and the cancer is breast cancer, gastric cancer, non-small cell lung cancer, bile duct cancer, colon cancer, ovarian cancer, or neuregulin-1 (NRG1)-positive cancer, (e) the protein that the Bm binds to is CD79b, R1 binds to IRAK4, and the cancer is a non-Hodgkin lymphoma, (f) the protein that the Bm binds to is HER2, R1 binds to BRD4, and and the cancer is breast cancer, gastric cancer, non-small cell lung cancer, bile duct cancer, colon cancer, ovarian cancer, or neuregulin-1 (NRG1)-positive cancer, or (g) the protein that the Bm binds to is BCMA, R1 binds to BRD4, and and the cancer is multiple myeloma.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of claim any one of claims 54 to 56, further comprising administering to the subject a pharmaceutically acceptable amount of an additional agent prior to, after, or simultaneously with the conjugate or composition of any one of claims 1 to 53, or a pharmaceutically acceptable salt thereof.

### Claim 58 (depends on 57)

The method of claim 57, wherein the additional agent is a cytotoxic agent or an immune response modifier.

### Claim 59 (depends on 58)

The method of claim 58, wherein the immune response modifier is a checkpoint inhibitor.

### Claim 60 (depends on 59)

The method of claim 59, wherein the checkpoint inhibitor comprises a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM3 inhibitor, and/or a LAG-3 inhibitor.

### Claim 61

A compound of formula (XXII):
or a pharmaceutically acceptable salt thereof, wherein:
n is 0 or 1;
R1 is a compound that induces a protein-protein interaction;
R2 is selected from hydrogen, —(CH2CH2O)v—CH3, C2-C6alkenyl, C1-C6alkyl; C2-C6alkynyl, benzyl, C3-C6cycloalkyl, and C3-C6cycloalkyl(C1-C3alkyl), wherein v is from 1 to 24;
each Y is independently S or O; and
L* is a cleavable linker precursor that conjugates to the binding moiety.

### Claim 62

A compound of formula (XXXI):
or a pharmaceutically acceptable salt thereof, wherein:
A′ is
wherein
n is 0 or 1;
each Y is independently S or 0;
indicates the point of attachment to R1; and
indicates the point of attachment to the methylene group;
R1, together with A′, is a compound that induces a protein-protein interaction;
R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-A′, and a group that provides stability and solubility to R1-A′; and
L is a cleavable linker precursor that conjugates to the binding moiety.

### Claim 63 (depends on 61, 62)

The compound of claim 61 or 62, or a pharmaceutically acceptable salt thereof, wherein L* is a protease cleavable linker precursor.

### Claim 64 (depends on 61, 62, 63)

The compound of any one of claims 61 to 63, or a pharmaceutically acceptable salt thereof, wherein L* is selected from the group consisting of
wherein:
q is from 2 to 10;
Z1, Z2, Z3, Z4, and Z5 are each independently absent or a naturally-occurring amino acid residue in the L- or D-configuration, provided that at least two of Z1, Z2, Z3, Z4, and Z5 are amino acid residues; and
is the point of attachment to the parent molecular moiety.

### Claim 65 (depends on 64)

The compound of claim 64, or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, Z4, and Z5 are independently absent or selected from the group consisting of L-valine, D-valine, L-citrulline, D-citrulline, L-alanine, D-alanine, L-glutamine, D-glutamine, L-glutamic acid, D-glutamic acid, L-aspartic acid, D-aspartic acid, L-asparagine, D-asparagine, L-phenylalanine, D-phenylalanine, L-lysine, D-lysine, and glycine; provided that at least two of Z1, Z2, Z3, Z4, and Z5 are amino acid residues.

### Claim 66 (depends on 65)

The compound of claim 65, or a pharmaceutically acceptable salt thereof, wherein:
Z1 is absent or glycine;
Z2 is absent or selected from the group consisting of L-glutamine, D-glutamine, L-glutamic acid, D-glutamic acid, L-aspartic acid, D-aspartic acid, L-alanine, D-alanine, and glycine;
Z3 is selected from the group consisting of L-valine, D-valine, L-alanine, D-alanine, L-phenylalanine, D-phenylalanine, and glycine;
Z4 is selected from the group consisting of L-citrulline, D-citrulline, L-asparagine, D-asparagine, L-lysine, D-lysine, L-phenylalamine, D-phenylalanine, and glycine; and
Z5 is absent or glycine.

### Claim 67 (depends on 61, 62, 63, 64, 65, 66)

The compound of any one of claims 61 to 66, or a pharmaceutically acceptable salt thereof, wherein L* is
wherein is the point of attachment to the parent molecular moiety.

### Claim 68 (depends on 67)

The compound of claim 67, or a pharmaceutically acceptable salt thereof, wherein q is 4.

### Claim 69 (depends on 61, 62)

The compound of claim 61 or 62, or a pharmaceutically acceptable salt thereof, wherein L* is a bioreducible linker precursor.

### Claim 70 (depends on 61, 62)

The compound of any one of claims 61, 62, or 69, or a pharmaceutically acceptable salt thereof, wherein L* is selected from the group consisting of
wherein:
q is from 2 to 10;
R, R′, R″, and R′″ are each independently selected from hydrogen, C1-C6alkoxyC1-C6alkyl, (C1-C6)2NC1-C6alkyl, and C1-C6alkyl, or, two geminal R groups, together with the carbon atom to which they are attached, can form a cyclobutyl or cyclopropyl ring;
is the point of attachment to the parent molecular moiety.

### Claim 71 (depends on 70)

The compound of claim 70, or a pharmaceutically acceptable salt thereof, wherein L* is

### Claim 72 (depends on 71)

The compound of claim 71, or a pharmaceutically acceptable salt thereof, wherein q is 2.

### Claim 73 (depends on 61, 62)

The compound of claim 61 or 62, or a pharmaceutically acceptable salt thereof, wherein L* is a click-to-release linker precursor.

### Claim 74 (depends on 73)

The compound of claim 73, or a pharmaceutically acceptable salt thereof, wherein L* is
wherein:
q is from 2 to 10; and
is the point of attachment to the parent molecular moiety.

### Claim 75 (depends on 61, 62)

The compound of claim 61 or 62, or a pharmaceutically acceptable salt thereof, wherein L* is a beta-glucuronidase cleavable linker precursor.

### Claim 76 (depends on 75)

The compound of claim 75, or a pharmaceutically acceptable salt thereof, wherein L* is
wherein:
q is from 2 to 10;
- - - is absent or a bond; and
is the point of attachment to the parent molecular moiety.

### Claim 77 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The compound of any one of claims 62 to 76, or a pharmaceutically acceptable salt thereof, wherein R2 is a group that provides stability to R1-A′.

### Claim 78 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The compound of any one of claims 62 to 77, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from C2-C6alkenyl, C1-C6alkyl; C2-C6alkynyl, benzyl, C3-C6cycloalkyl, and C3-C6cycloalkyl(C1-C3alkyl),

### Claim 79 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 62 to 78, or a pharmaceutically acceptable salt thereof, wherein R2 is C1-C6alkyl.

### Claim 80 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The compound of any one of claims 62 to 79, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl.

### Claim 81 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The compound of any one of claims 62 to 76, or a pharmaceutically acceptable salt thereof, wherein R2 is a group that provides solubility to R1-A′.

### Claim 82 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 81)

The conjugate of any one of claims 62 to 76 or 81, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from:
wherein:
each n is independently 1, 2, 3, 4, or 5;
each y is independently 1 or 2;
each R is independently hydrogen, C6H11O5, C12H21O10, C18H31O15, or C24H41O20.

### Claim 83 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The compound of any one of claims 61 to 82, or a pharmaceutically acceptable salt thereof, wherein each Y is O.

### Claim 84 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The compound of any one of claims 62 to 83, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a PPI modulator.

### Claim 85 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The compound of any one of claims 62 to 83, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a targeted protein degrader.

### Claim 86 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The compound of any one of claims 62 to 83, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a molecular glue.

### Claim 87 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The compound of any one of claims 62 to 86, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a substituted isoindoline.

### Claim 88 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The compound of any one of claims 62 to 87, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a 5′-substituted isoindoline.

### Claim 89 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The compound of any one of claims 61 to 88, or a pharmaceutically acceptable salt thereof, wherein R1 has the formula:
wherein:
denotes the point of attachment to the parent molecular moiety;
A is phenyl or a C4-C10cycloalkyl ring;
R10 is independently selected from hydrogen and halo;
U is selected from NH and CF2; and
R20 is selected from —CH3, —C(O)R3, —N(R4)2, —(CH2)nOH, —(CH2)nN(R4)2, —(CH2)nQ′(CH2)mOH, —(CH2)nQ′(CH2)mSH, and —(CH2)nQ′(CH2)mN(R4)2; wherein
R3 is hydrogen or C1-C6alkyl;
each R4 is independently hydrogen or C1-C6alkyl;
Q′ is O, S, or NR4;
n is 1-6; and
m is 2-5.

### Claim 90 (depends on 89)

The compound of claim 89, or a pharmaceutically acceptable salt thereof, wherein
A is phenyl;
U is NH;
R10 is halo; and
R20 is methyl.

### Claim 91 (depends on 89)

The compound of claim 89, or a pharmaceutically acceptable salt thereof, wherein
A is phenyl;
U is NH;
R10 is halo; and
R20 is —(CH2)2O(CH2)2NHCH3.

### Claim 92 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The compound of any one of claims 62 to 85, or a pharmaceutically acceptable salt thereof, wherein R1-A′ is a proteolysis targeting chimera (PROTAC).

### Claim 93 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 92)

The compound of any one of claims 61 to 85 or 92, or a pharmaceutically acceptable salt thereof, wherein R1 has the formula:
POI-L100-CBN;
wherein:
POI is a compound that binds to a protein of interest;
L100 is a PROTAC linker; and
CBN is a cereblon binding moiety.

### Claim 94 (depends on 93)

The compound of claim 93, or a pharmaceutically acceptable salt thereof, wherein the protein of interest is a nuclear hormone receptor, a translation termination factor, a transcription factor, a cyclin-dependent kinase, a tyrosine kinase, a serine/threonine kinase, or an E3 ligase.

### Claim 95 (depends on 93, 94)

The compound of claim 93 or 94, or a pharmaceutically acceptable salt thereof, wherein the protein of interest is selected from CD33, GSPT1, BRD4, AR, ER, IKZF1/3, CK1a, BCL-XL, IKZF2, IRAK4, BTK, STAT3, BTK and iMiD, BRD9, TRK, MDM2, CDK2/CDK9, CD97b, and EGFR.

### Claim 96 (depends on 93, 94, 95)

The conjugate of any one of claims 93 to 95, or a pharmaceutically acceptable salt thereof, wherein L100 comprises one or more functional groups selected from glycol, alkyl, alkynyl, triazolyl, piperazinyl, piperidinyl, and combinations thereof.

### Claim 97 (depends on 93, 94, 95, 96)

The conjugate of any one of claims 93 to 96, or a pharmaceutically acceptable salt thereof, wherein CBN is selected from
wherein
indicates the point of attachment to A′; and
indicates the point of attachment to L100.

### Claim 98 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 92, 93, 94, 95, 96, 97)

The compound of any one of claims 62 to 85 or 92 to 97, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from
wherein denotes the point of attachment to A′.

### Claim 99

A method for preparing a conjugate of formula (XXXII):
or a pharmaceutically acceptable salt thereof, wherein:
a is from 1 to 10;
A′ is
wherein
n is 0 or 1;
each Y is independently S or 0;
indicates the point of attachment to R1; and
indicates the point of attachment to the methylene group;
R1, together with A′, is a compound that induces a protein-protein interaction;
R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-A′, and a group that provides stability and solubility to R1-A′;
L is a cleavable linker; and
Bm is a binding moiety that is capable of specifically binding to a protein;
the method comprising:
reacting a compound of (XXXI)
or a pharmaceutically acceptable salt thereof, wherein:
A′, R1, and R2 are as defined above and
L* is a cleavable linker precursor;
with a binding moiety that is capable of specifically binding to a protein.

### Claim 100 (depends on 99)

The method of claim 99, further comprising attaching L* to a cysteine, lysine, tyrosine, or glutamine in the Bm.

### Claim 101 (depends on 100)

The method of claim 100, wherein the cysteine or lysine is an engineered cysteine or lysine.

### Claim 102 (depends on 100)

The method of claim 100, wherein the cysteine or lysine is endogenous to the Bm.

### Claim 103 (depends on 99)

The method of claim 99, wherein the binding moiety is an antibody or an antigen binding portion thereof.

### Claim 104 (depends on 103)

The method of claim 103, wherein L* is attached to an engineered cysteine at heavy chain position S239 and/or K334 of the antibody or antigen binding portion thereof according to EU numbering.

### Claim 105 (depends on 103)

The method of claim 103, wherein L* is attached to the glutamine at heavy chain position 295 of the antibody or antigen binding portion thereof according to EU numbering.

### Claim 106 (depends on 100, 101, 102, 103, 104, 105)

The method of any one of claims 100 to 105, wherein the attaching is via site-specific conjugation.

### Claim 107 (depends on 100, 101, 102, 103, 104, 105, 106)

The method of any one of claims 100 to 106, wherein (a) the protein that the Bm binds to is CD33 and R1 binds to mouse double minute 2 homolog (MDM2), (b) the protein that the Bm binds to is prostate specific membrane antigen (PSMA) and R1 binds to androgen receptor (AR), (c) the protein that the Bm binds to is CD33 and R1 binds to bromodomain-containing protein 4 (BRD4), (d) the protein that the Bm binds to is HER2 and R1 binds to G1 to S Phase Transition 1 (GSPT1), (e) the protein that the Bm binds to is CD33 and R1 binds to GSPT1, (f) the protein that the Bm binds to is CD79b and R1 binds to IRAK4, (g) the protein that the Bm binds to is HER2 and R1 binds to BRD4, (h) the protein that the Bm binds to is BCMA and R1 binds to BRD4, or (i) the protein that the Bm binds to is HER2 and R1 binds to ER.

### Claim 108 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107)

The method of any one of claims 99 to 107, wherein R1-A′ is a targeted protein degrader.

### Claim 109

The method of 108, wherein R1 has the formula:
POI-L100-CBN;
wherein:
POI is a compound that binds to a protein of interest;
L100 is a PROTAC linker; and
CBN is a cereblon binding moiety.

### Claim 110 (depends on 109)

The method of claim 109, wherein the protein of interest is a nuclear hormone receptor, a translation termination factor, a transcription factor, a cyclin-dependent kinase, a tyrosine kinase, a serine/threonine kinase, or an E3 ligase

### Claim 111 (depends on 109, 110)

The method of claim 109 or 110, wherein the protein of interest is selected from CD33, GSPT1, BRD4, AR, ER, IKZF1/3, CK1a, BCL-XL, IKZF2, IRAK4, BTK, STAT3, BTK and iMiD, BRD9, TRK, MDM2, CDK2/CDK9, CD97b, and EGFR.

### Claim 112 (depends on 109, 110, 111)

The conjugate of any one of claims 109 to 111, or a pharmaceutically acceptable salt thereof, wherein L100 comprises one or more functional groups selected from glycol, alkyl, alkynyl, triazolyl, piperazinyl, piperidinyl, and combinations thereof.

### Claim 113 (depends on 109, 110, 111, 112)

The method of any one of claims 109 to 112, or a pharmaceutically acceptable salt thereof, wherein CBN is selected from:
wherein
indicates the point of attachment to A′; and
indicates the point of attachment to L100.

### Claim 114 (depends on 109, 110, 111, 112, 113)

The method of any one of claims 109 to 113, wherein R1 is selected from:
wherein denotes the point of attachment to A′.

### Claim 115 (depends on 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

A conjugate made by the method of any one of claims 99 to 114.

### Claim 116 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 115)

A method of delivering a conjugate that induces a protein-protein interaction to a cell, the method comprising contacting the cell with a conjugate or composition of any one of claims 1 to 53 or 115, or a pharmaceutically acceptable salt thereof.

### Claim 117

A method of delivering a conjugate of formula (XXXII):
or a pharmaceutically acceptable salt thereof to a cell, wherein:
a is from 1 to 10;
A′ is
wherein
n is 0 or 1;
each Y is independently S or 0;
indicates the point of attachment to R1; and
indicates the point of attachment to the methylene group;
R1, together with A′, is a compound that induces a protein-protein interaction;
R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-′A, and a group that provides stability and solubility to R1-A′;
L is a cleavable linker; and
Bm is a binding moiety that is capable of specifically binding to a protein;
the method comprising contacting the cell with a conjugate of formula (XXXII), or a pharmaceutically acceptable salt thereof.
